Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of 1 of the following:
• •* Aplastic anemia not responsive to immunosuppressive therapy
• •* Metastatic renal cell carcinoma
• •* Hematologic malignancy, including any of the following:
• •* Acute myeloid leukemia (AML)\* not curable with chemotherapy and meeting any of the following criteria:
• •* AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q, complex, Philadelphia chromosome-positive \[Ph+\])
• •* AML evolved from prior myelodysplasia
• •* AML secondary to prior chemotherapy
• •* Failed to achieve remission
• •* In second or subsequent remission NOTE: \*Marrow blasts \< 10%- can be achieved by chemotherapy
• •* Myelodysplasia\* with any of the following high-risk features:
• •* Adverse cytogenetics (-7, 7q, -5, -5q, complex)
• •* Excess blasts
• •* Prior conversion to AML
• •* Severe cytopenias with absolute neutrophil count \< 500/mm\^3 or platelet count \< 20,000/mm\^3 NOTE: \*Marrow blasts \< 10%- can be achieved by chemotherapy
• •* Acute lymphoblastic leukemia (ALL)\* not curable with chemotherapy and meeting any of the following criteria:
• •* High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7)
• •* More than 1 induction course required to achieve remission
• •* Failed to enter remission
• •* In second or subsequent remission NOTE: \*Marrow blasts \< 10 %
• •* Chronic lymphocytic leukemia (CLL) with high-risk features, including any of the following:
• •* Refractory to initial or subsequent therapy
• •* Progression after initial response to therapy
• •* Prolymphocytic morphology
• •* Follicular lymphoma with any of the following high-risk features:
• •* Refractory to initial or subsequent therapy
• •* Progression after response to initial therapy
• •* Has ≥ 3 International Prognostic Index (IPI) risk factors
• •* Multiple myeloma
• •* Stage II-III disease confirmed at diagnosis or after initial progression
• •* Other lymphoma that has failed to respond to primary therapy, progressed, or recurred after prior therapy, including any of the following:
• •* Diffuse large cell lymphoma
• •* Mantle cell lymphoma
• •* Hodgkin's lymphoma
• •* Myeloproliferative disease with evidence of disease acceleration, including any of the following:
• •* Myelofibrosis
• •* Polycythemia vera
• •* Essential thrombocythemia
• •* Chronic myeloid leukemia (CML) that failed to be controlled by imatinib mesylate
• •Disease must be stable or responding to therapy
• •No rapid progression of malignant disease
• •* Expected time to disease progression \> 12 weeks